Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications

Oryzon Genomics (ISIN Code: ES0167733015 , ORY ), a public clinical - stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has designated its next drug, ORY - 3001 , for preclinical development. This is the third drug candidate produced by the Company , a first - in - class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of , yet undisclosed , non - oncological conditions.

Oryzon has a highly competitive and productive Epigenetics Platform , centered around the development of LSD1 inhibitors , with a first drug currently in Phase IIA in acute leukemia that validates the platform scientifically and clinically. This Platform has so far produced two compounds in clinical development with multiple indication opportunities for both drugs.

LSD1 is an enzyme that removes methyl marks from lysine 4 of histone H3 , a nucleosomal protein involved in the organization and control of accessibility of DNA for transcription. Modification s of these histone marks are associated with changes in gene transcription. Modulation of LSD1 activity can be used to change the transcriptional balance in cells, and LSD1 has been suggested to be a potential target for certain cancer types, for neurodegenerative disorders, for treatment of viral infections, and other indications.

Oryzon’s LSD1 drugs are pioneering the Histone demethylases field with its forerunner oncologic drug that was licensed to Roche in 2014 and a second program in Phase I in neurodegenerative disorders. The company will focus its therapeutic efforts with this third drug preferentially in non - oncological orphan indications.

ORY - 3001 is an enantiomerically pure, potent and selective compound with good pharmacological properties, orally bioavailable, with optimal PK, safety and selectivi ty profile. After successful completion of regulatory toxicology studies, the company expects to move ORY - 3001 into Clinical Phase I/IIa studies in the H2 of 2017 .